Effectiveness of MAID Therapy against Metastatic Malignant Phyllodes Tumors and Stromal Sarcoma of the Breast

Yonemori, Kan; Shimizu, Chikako; Hasegawa, Tadashi; Matsumoto, Koji; Kouno, Tsutomu; Yamanaka, Yasuhiro; Ando, Masashi; Katsumata, Noriyuki; Fujiwara, Yasuhiro

doi:10.1159/000093319

Cited by 6 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Few studies discuss the treatment for patients with metastatic PTs. However, the results of these few studies seem promising as nearly half of the patients exhibited partial responses to treatment [20,35].…”

Section: Discussionmentioning

confidence: 99%

Adjuvant radiotherapy and chemotherapy for patients with breast phyllodes tumors: a systematic review and meta-analysis

Xue

Chen

Zeng³

et al. 2019

BMC Cancer

View full text Add to dashboard Cite

Background: As the efficacy of radiotherapy and chemotherapy for treatment of phyllodes tumors (PTs) remains unclear, this study aimed to review all available data and evaluate the roles of radiotherapy and chemotherapy in PT treatment. Methods: We performed a comprehensive search of databases, including PubMed, Web of Science and the Cochrane Library. The outcomes of interest included the local recurrence (LR) rate, metastasis rate, disease-free survival rate and overall survival rate. Results: Seventeen studies enrolling 696 patients were included in this random effect meta-analysis. Subgroup analysis and meta-regression were also conducted to determine study heterogeneity. A pooled local recurrence rate of 8% (95% CI: 1-22%) was observed with a statistical heterogeneity of I 2 = 86.6% (p < 0.01) for radiotherapy. This was lower than the recurrence rate of 12% for simple surgical treatment (95% CI: 7-18%). Meta-regression analysis found that surgical margin status was the main source of heterogeneity (p = 0.04). The metastasis rate of 4% (95% CI: 0-11%) for patients receiving radiotherapy without significant heterogeneity was also lower than the rate for the simple surgery group (8, 95% CI: 3-15%). The available data for chemotherapy were too limited to support meta-analysis. Accordingly, we offer a pure review of these data. Conclusion: Our findings suggest that radiotherapy is effective in achieving local disease control and preventing metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Adjuvant radiotherapy and chemotherapy for patients with breast phyllodes tumors: a systematic review and meta-analysis

Xue

Chen

Zeng³

et al. 2019

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…In addition, most available data derive from case reports or studies involving chemotherapy for metastatic PTs. [17][18][19][20][21] Two retrospective studies 19,20 specifically addressing systemic treatment of metastatic phyllodes tumors revealed that patients with metastatic disease who underwent anthracycline-based (AI/anthracycline alone/other anthracycline regimens) chemotherapy regimens, particularly the AI regimen, experienced enhanced survival benefits. According to Palassini et al, 19 66.1% (37/56) of patients with metastatic MPTs opted for anthracycline-based chemotherapy regimens, comparable to the 64% (32/50) according to Parkes et al 20 Similarly, most (74.2%) patients in our study received anthracycline-based chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

The Impact of Adjuvant Chemotherapy on the Long-Term Prognosis of Breast Malignant Phyllodes Tumors: A Propensity Score–Matched Study

Zhuang,

Yilihamu,

et al. 2024

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

Background: Malignant phyllodes tumors (MPTs) are rare breast tumors with high risks of local recurrence and distant metastasis. Surgical intervention is the primary treatment, but the effectiveness of adjuvant therapies is uncertain. This study was designed to analyze the prognostic risk factors associated with MPTs and evaluate the efficacy of postoperative adjuvant chemotherapy. Patients and Methods: Patients who were first diagnosed with MPT without distant metastasis and received R0 resection surgery between 1999 and 2023 were included in the present study and stratified into 2 groups: chemotherapy and nonchemotherapy groups. Propensity score matching (PSM) was used to balance baseline characteristics between groups. Kaplan-Meier curves were used to estimate local recurrence–free survival (LRFS) and overall survival (OS). Cox proportional hazards analyses (univariate and multivariate) were conducted to identify prognostic risk factors. Results: We conducted a study involving 145 patients, 31 of whom underwent a total of 12 different chemotherapy regimens following initial surgical resection. Most patients received chemotherapy regimens primarily consisting of anthracyclines, including anthracycline + ifosfamide (AI) or anthracycline + cyclophosphamide/docetaxel (AC-T) regimens. After a median follow-up of 54.5 months, 37 (25.5%) patients experienced local recurrence and 24 (16.6%) experienced distant metastasis. No significant difference was detected in the rates of local recurrence or distant metastasis between the 2 groups. Axillary lymph node positivity was the only risk factor for LRFS, whereas older age, larger tumors, axillary lymph node positivity, local recurrence, and distant metastasis were significantly associated with worse OS. Chemotherapy did not emerge as a protective factor for LRFS (P=.501) or OS (P=.854). After PSM, patients in the chemotherapy group did not exhibit better 5-year LRFS (P=.934) or 5-year OS (P=.328). Conclusions: According to our retrospective evaluation, postoperative adjuvant chemotherapy was not associated with improved survival in patients with MPTs without distant metastasis.

show abstract

“…ont traité 8 patientes par une chimiothérapie intensifiée comportant doxorubicine, dacarbazine, ifosfamide et mesna. Une réponse partielle a été mise en évidence chez 4 patientes au prix d´une toxicité hématologique de grade 3 avec une médiane de survie de 5 mois [ 9 ]. À travers les différentes études citées, on constate qu´un régime de chimiothérapie muli-agent à base de doxorubicine est le plus souvent utilisé avec une efficacité qui paraît légèrement supérieure de la polychimiothérapie par rapport à la monochimiothérapie.…”

Section: Discussionunclassified

Quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas

Ait¹,

Bourhafour²,

Haffadi³

et al. 2022

Pan Afr Med J

View full text Add to dashboard Cite

Les tumeurs phyllodes (TP) du sein sont rares. Elles peuvent revêtir un caractère bénin, borderline ou malin. La forme maligne représente 20-30% des TP avec des métastases à distance dans 10-26% des cas. La chimiothérapie est l´une des principales armes thérapeutiques des tumeurs phyllodes métastatiques (TPM). Nous rapportons quatre cas de TPM du sein prises en charge au centre Mohamed VI de Casablanca pour le traitement des cancers de janvier 2015 à décembre 2017. L´âge de nos patientes était compris entre 25 et 45 ans. Le mode de révélation clinique est représenté, dans la majorité des cas, par l´apparition d´une énorme masse mammaire et le diagnostic histologique a été porté chez toutes les patientes sur la pièce de mastectomie. Trois patientes étaient métastatiques au niveau du poumon, deux avaient des métastases ganglionnaires axillaires, deux avaient des métastases osseuses et une seule avait des métastases hépatiques. Toutes les patientes ont reçu une chimiothérapie. Les drogues utilisées étaient: la doxorubicine en monothérapie et l´association doxorubicine-ifosfamide (AI). Une seule patiente a eu une évolution très favorable avec une réponse radiologique complète après 3 cures d´AI. Les TPM du sein sont de mauvais pronostic. L´intérêt d´une chimiothérapie systémique reste à définir surtout qu´on ne dispose pas jusqu´à présent de données concernant la chimiothérapie optimale.

show abstract

Effectiveness of MAID Therapy against Metastatic Malignant Phyllodes Tumors and Stromal Sarcoma of the Breast

Cited by 6 publications

References 15 publications

Adjuvant radiotherapy and chemotherapy for patients with breast phyllodes tumors: a systematic review and meta-analysis

Adjuvant radiotherapy and chemotherapy for patients with breast phyllodes tumors: a systematic review and meta-analysis

The Impact of Adjuvant Chemotherapy on the Long-Term Prognosis of Breast Malignant Phyllodes Tumors: A Propensity Score–Matched Study

Quelle chimiothérapie dans les tumeurs phyllodes métastatiques du sein? rapport de cas

Contact Info

Product

Resources

About